Molecular Partners (MOLN) Competitors

Sage Therapeutics (NASDAQ:SAGE) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Which has stronger valuation & earnings, SAGE or MOLN?

Molecular Partners has lower revenue, but higher earnings than Sage Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sage Therapeutics	$41.24M	13.96	-$400.67M	-$5.80	-1.59
Molecular Partners	$5.65M	26.59	-$61.39M	-$1.92	-1.94

Does the media favor SAGE or MOLN?

In the previous week, Sage Therapeutics had 4 more articles in the media than Molecular Partners. MarketBeat recorded 6 mentions for Sage Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.37 beat Sage Therapeutics' score of 0.18 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sage Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is SAGE or MOLN more profitable?

Molecular Partners has a net margin of 0.00% compared to Sage Therapeutics' net margin of -747.63%. Molecular Partners' return on equity of -42.20% beat Sage Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sage Therapeutics	-747.63%	-68.99%	-60.67%
Molecular Partners	N/A	-42.20%	-38.12%

Which has more volatility & risk, SAGE or MOLN?

Sage Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Do analysts rate SAGE or MOLN?

Sage Therapeutics currently has a consensus target price of $8.93, suggesting a potential downside of 2.85%. Molecular Partners has a consensus target price of $12.00, suggesting a potential upside of 222.58%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts clearly believe Molecular Partners is more favorable than Sage Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sage Therapeutics	1 Sell rating(s)	15 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Do insiders and institutionals hold more shares of SAGE or MOLN?

99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Molecular Partners beats Sage Therapeutics on 12 of the 16 factors compared between the two stocks.